Loading the company…
Loading the company…
Families: Peripheral arterial intervention.
All companies · Product and company coverage
In the last ten years FDA made 1 decision for Nipro Medical (510(k) clearances, De Novo grants, PMA approvals and supplements) under the product codes MedaRep maps to 1 procedure family, the most in 2019 (1). The latest was on 2019-10-24.
| Family | Decisions on record |
|---|---|
| Peripheral arterial intervention | 2 |
| Date | Kind | Number | Device |
|---|---|---|---|
| 2019-10-24 | 510(k) | K190037 | Cronus HP PTA Balloon Catheter |
| 2016-01-14 | 510(k) | K151141 | Cronus HP - High Pressure Peripheral Balloon Catheter |
Decisions under the product codes mapped to the procedure families; devices filed under other codes are not here. Applicants are rolled up to Nipro Medical.
In 2025, Nipro Medical reported engagement with 56 surgeons and other clinicians in the states MedaRep covers, worth $29K in consulting, speaking, meals and travel for its device products, the most in Virginia ($12K to 1). Royalties are left out.
Spend tied to a procedure counts the payments whose product names it. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing.Top states by spend: Virginia ($12K, 1 engaged), Georgia ($6,363, 1 engaged), California ($6,301, 6 engaged), New York ($918, 4 engaged), Louisiana ($687, 4 engaged).